Regulation of Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) Channel Activity by cCMP

Xiangang Zong‡, Stefanie Krause†, Cheng-Chang Chen‡, Jens Krüger‡, Christian Gruner‡, Xiaochun Cao-Ehlker‡, Stefanie Fenske‡, Christian Wahl-Schott‡, and Martin Biel††

From the ‡Center for Integrated Protein Science (CIPSM) and Zentrum für Pharmaforschung, Department Pharmazie, Ludwig-Maximilians-Universität München, 80539 Munich and the †Applied Bioinformatics Group, Wilhelm Schickard Institute for Computer Science, Eberhard Karls Universität Tübingen, 72076 Tübingen, Germany

Received for publication, February 28, 2012, and in revised form, June 13, 2012. Published, JBC Papers in Press, June 19, 2012, DOI 10.1074/jbc.M112.357129

To whom correspondence should be addressed: Dept. Pharmazie, Pharmakologie für Naturwissenschaften, Ludwig-Maximilians-Universität München, Butenandstr, 5-13, 81377 Munich, Germany. Tel.: 49-89-2180-77372; Fax: 49-89-2180-77326; E-mail: martin.biel@cup.uni-muenchen.de.

Background: HCN channels are dually gated by membrane hyperpolarization and binding of cAMP.

Results: We identify cCMP as a novel regulator of heterologously expressed and native HCN channels.

Conclusion: HCN channels are cellular receptors for cCMP.

Significance: Modulatory effects of cCMP must be considered when studying physiological effects involving HCN channels.

Activation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels is facilitated in vivo by direct binding of the second messenger cAMP. This process plays a fundamental role in the fine-tuning of HCN channel activity and is critical for the modulation of cardiac and neuronal rhythmicity. Here, we identify the pyrimidine cyclic nucleotide cCMP as another regulator of HCN channels. We demonstrate that cCMP shifts the activation curves of two members of the HCN channel family, HCN2 and HCN4, to more depolarized voltages. Moreover, cCMP speeds up activation and slows down deactivation kinetics of these channels. The two other members of the HCN channel family, HCN1 and HCN3, are not sensitive to cCMP. The modulatory effect of cCMP is reversible and requires the presence of a functional cyclic nucleotide-binding domain. We determined an EC50 value of ~30 μM for cCMP compared with 1 μM for cAMP. Notably, cCMP is a partial agonist of HCN channels, displaying an efficacy of ~0.6. cCMP increases the frequency of pacemaker potentials from isolated sinoatrial pacemaker cells in the presence of endogenous cAMP concentrations. Electrophysiological recordings indicated that this increase is caused by a depolarizing shift in the activation curve of the native HCN current, which in turn leads to an enhancement of the slope of the diastolic depolarization of sinoatrial node cells. In conclusion, our findings establish cCMP as a gating regulator of HCN channels and indicate that this cyclic nucleotide has to be considered in HCN channel-regulated processes.

Hyperpolarization-activated cyclic nucleotide-gated (HCN)2 ion channels play a key role in controlling excitability of neurons and heart cells (1–3). In particular, the current produced by HCN channels, called Ih, in heart or In, in neurons, is involved in the generation of sinoatrial pacemaker potentials that trigger the autonomous heartbeat (4). The four members of the HCN channel family (HCN1–4) are principally gated by membrane hyperpolarization (5–7). In addition, HCN channel activity is enhanced by direct binding of cAMP to a cyclic nucleotide-binding domain (CNBD) in the C terminus of the channels. This type of channel regulation plays an important role in a variety of physiological settings. For example, cAMP-dependent up-regulation of Ih in sinoatrial node (SAN) cells contributes to the increase in heart rate following sympathetic stimulation (8), whereas down-regulation of Ih at low cAMP levels leads to the decrease in heart rate in response to vagal stimulation (9). cAMP-dependent regulation of Ih is also implicated in the modulation of neuronal circuit activity that controls complex brain functions such as sleep phases (10), memory formation (11), and coincidence detection of sound (12).

The purine cyclic nucleotides cAMP and cGMP are well established second messengers that confer the cellular effects of a wide range of hormones and neurotransmitters. By contrast, the natural existence of the pyrimidine 3′,5′-monophosphates cCMP and cUMP has been debated (13–17). However, recent highly sensitive liquid chromatography/mass spectrometry approaches have confirmed that many cell types contain micromolar concentrations of cCMP and cUMP (18). Although a specific cCMP receptor has not yet been identified, it was shown that this cyclic nucleotide cross-activates cAMP- and cGMP-dependent protein kinases (19). In particular, cCMP was found to relax aortic smooth muscle by activating cGMP-dependent protein kinase type I (20). cCMP was also shown to inhibit platelet aggregation via cGMP-dependent protein kinase type I signaling (20). The CNBDs of cGMP-dependent protein kinases reveal strong sequence homology to the CNBDs of HCN channels (1). Given this structural relationship, we wondered whether HCN channels may be also regulated by interaction with cCMP. In support of this hypothesis, cCMP was shown to affect native Ih in excised patches from rabbit SAN cells (21). In this study, we examined the functional interaction between cCMP and each of the four HCN channel types. We...
also studied the co-modulation of HCN channel activity by combinations of cAMP and cCMP. Finally, we set out to study the consequences of cCMP-dependent HCN channel regulation in native SAN cells.

**EXPERIMENTAL PROCEDURES**

*Electrophysiology in HEK293 Cells*—HEK293 cell lines stably expressing murine HCN1–4 were maintained as described (22). Currents were measured from HEK293 cells stably expressing one of the four murine HCN channel types at room temperature using the whole-cell voltage-clamp technique. The extracellular solution was composed of 110 mM NaCl, 30 mM KCl, 1.8 mM CaCl₂, 0.5 mM MgCl₂, and 5 mM HEPES (pH adjusted to 7.4 with NaOH). The intracellular solution contained 130 mM KCl, 10 mM NaCl, 0.5 mM MgCl₂, 1 mM EGTA, 5 mM HEPES, 3 mM MgATP, and 0.5 mM NaGTP (pH adjusted to 7.4 with KOH). cAMP (Sigma), cCMP (BioLog), and cUMP (BioLog) were added to the intracellular solution at the indicated concentrations. Steady-state activation curves were determined by hyperpolarizing voltage steps from −140 to −30 mV in 10-mV increments from a holding potential of −40 mV for 1.8 s (for HCN1 and HCN2, pulse interval of 10 s) or 3.6 s (for HCN3 and HCN4, pulse interval of 20 s), followed by a step to −140 mV (see Fig. 1A). Currents measured immediately after the final step to −140 mV were normalized by the maximal current (\(I_{\text{max}}\)) and plotted as a function of the preceding membrane potential (see Fig. 1A, arrowheads). The data points were fitted with the Boltzmann function: \(I = I_{\text{min}}/(I_{\text{max}} - I_{\text{min}}) = 1 - \exp((V_m - V_{0.5})/k)\), where \(I_{\text{min}}\) is an offset caused by a nonzero holding current, \(V_m\) is the test potential, \(V_{0.5}\) is the membrane potential for half-maximal activation, and \(k\) is the slope factor. The deactivation kinetics were measured at −40 mV following a prepulse of −140 mV, and the time constant was determined by fit with a monoeponential function starting after the initial deactivation delay.

*Electrophysiology on SAN Cells*—SAN cells were isolated from 6–8-week-old adult female mice using standard procedures (23). Measurements in SAN cells were performed in the whole-cell configuration. Single SAN cells were plated onto poly-L-lysine-coated coverslips. The pipette solution contained 130 mM potassium aspartate, 10 mM NaCl, 2 mM CaCl₂, 2 mM MgCl₂, 5 mM EGTA, 2 mM NaGTP, 0.1 mM NaGTP, and 5 mM creatine phosphate (pH adjusted to 7.2 with KOH). \(I_V\) was recorded at room temperature in bath solution containing 138 mM NaCl, 4 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 5 mM EGTA, 10 mM HEPES, 10 mM glucose, 2 mM BaCl₂, and 0.3 mM CdCl₂ (pH adjusted to 7.2 with NaOH). Currents were recorded by stepping from a holding potential of −35 mV to test potentials ranging from −150 to −40 mV in 10-mV increments for 5.5 s, followed by a step to −150 mV for 0.5 s before stepping back to the holding potential. Action potentials were recorded at \(33 \pm 0.5^\circ C\) in bath solution containing 140 mM NaCl, 5.4 mM KCl, 1 mM MgCl₂, 1.8 mM CaCl₂, 10 mM HEPES, and 10 mM glucose (pH adjusted to 7.4 with NaOH). The effect of cCMP and cAMP was tested by adding cCMP or cAMP to the pipette solution as indicated. Changes in liquid junction potentials were either calculated using JPCalc software (24) or directly measured by a free-flowing KCl electrode. The liquid junction potential was −13.9 mV for solutions used for action potential recording.

For determination of the slope of the diastolic depolarization (SDD), the local means of several \((n = 25–45)\) successive spontaneous action potentials were averaged. The diastolic depolarization was defined as the phase of the action potential in the interval between the maximal diastolic potential and the time when the voltage derivative (dV/dt) overtakes a threshold of 0.5 mV/ms (25). In experiments involving HEK cell lines and SAN cells, data were acquired at 10 kHz using an Axopatch 200B amplifier and pCLAMP 10.2 (Molecular Devices). Voltage-clamp data were analyzed off-line using Clampfit 10.2 and Origin 6.1.

*Planar Patch-clamp Technology*—To examine the kinetics of HCN channel activation by intracellular cCMP, the planar patch-clamp technology combined with a fast internal perfusion system (Port-a-Patch, Nanion Technologies, Munich, Germany) was used (26). Currents were recorded using an EPC-10 patch-clamp amplifier (HEKA, Lambrecht, Germany) and PatchMaster acquisition software (HEKA). Data were digitized at 40 kHz and filtered at 2.8 kHz. Fast and slow capacitive transients were cancelled by the compensation circuit of the EPC-10 amplifier. All recordings were obtained at room temperature. The extracellular solution was composed of 110 mM NaCl, 30 mM KCl, 1.8 mM CaCl₂, 0.5 mM MgCl₂, and 5 mM HEPES (pH adjusted to 7.4 with NaOH). The intracellular solution contained 70 mM KCl, 60 mM KF, 10 mM NaCl, 0.5 mM MgCl₂, and 5 mM HEPES (pH adjusted to 7.4 with KOH). Currents were evoked from a holding potential of −40 mV by applying 5-s voltage pulses to −100 mV every 10 s. The effects of cyclic nucleotides were examined by exchanging the standard internal solution with internal solutions supplemented with either cCMP or cAMP using the internal perfusion system. To monitor the time course of HCN channel rundown, the cells were internally perfused with the standard internal solution without cyclic nucleotides.

*Modeling*—The crystal structures of CNBDs of murine HCN2 and human HCN4 were used (Protein Data Bank codes 1Q43 and 3U11) as receptors for docking (27, 28). Calculations were carried out with MOE (Molecular Operating Environment) 2010.10 (Chemical Computing Group, Montreal, Canada). The binding site selection was based on the Site Finder module of MOE, marking the cyclic nucleotide-binding pocket with dummy atoms (29). Different ligand placement methods available in MOE (Triangle Matcher, Alpha PMI, and Alpha Triangle) were used to estimate the binding energies of cAMP and cCMP toward HCN2 and HCN4. Binding affinities were estimated with the London dG scoring function after a force field-based refinement and rescoring. During refinement, a tethered rearrangement of side chains within 6 Å of the ligand was allowed. The MMFF94s force field with a generalized Born solvation model was used for all docking calculations. Plots and figures were created with MOE.

*Statistics*—For electrophysiological data, statistical analysis was performed by one-way analysis of variance. Data are presented as means ± S.E. \((n = \text{number of recorded cells})\). Values of \(p < 0.05\) were considered significant.
cCMP is an Activator of HCN Channels

FIGURE 1. Modulation of HCN2 current by cCMP. A, voltage step protocol and family of current traces of HEK293 cells stably expressing HCN2 without (left) and with (right) 1 mM cCMP in the pipette solution. B, normalized activation curves of HCN2 in the presence (■) and absence (●) of 1 mM cCMP. The solid lines are the fits to the Boltzmann equation with the following parameters: in the absence of cCMP (n = 15), \( V_{0.5} = -102 \pm 0.67 \text{ mV} \) and \( k = 6.34 \pm 0.71 \text{ mV} \) and in the presence of cCMP (n = 14), \( V_{0.5} = -93.8 \pm 0.54 \text{ mV} \) and \( k = 6.53 \pm 0.76 \text{ mV} \). C, normalized current traces of HCN2 in the absence and presence of 1 mM cCMP. Currents were evoked by a hyperpolarizing step to \(-140 \text{ mV}\) from a holding potential of \(-40 \text{ mV}\), followed by a voltage pulse to \(-40 \text{ mV}\). Maximal currents at \(-140 \text{ mV}\) were normalized. D, display of current traces during HCN2 channel deactivation at \(-40 \text{ mV}\) (area within the dotted box in C).

RESULTS

Regulation of HCN2- and HCN4-mediated Currents by cCMP—We studied the effect of cCMP on \( I_{h} \) in a HEK293 cell line stably expressing HCN2 (Fig. 1). Fig. 1A shows representative families of current traces measured in the whole-cell mode under control conditions and after intracellular application of 1 mM cCMP via the patch pipette. cCMP had two effects on the HCN2-mediated current. First, it shifted the voltage dependence of activation to \(-8 \text{ mV}\) more positive values (Fig. 1B). Second, cCMP affected the activation and deactivation kinetics of the current. In the presence of cCMP, the current activated significantly faster than in the absence of cCMP (\( \tau_{\text{act}} \) at \(-140 \text{ mV}\) = 185 \pm 9.3 ms (n = 14) versus 307 \pm 10.5 ms (n = 15) in the absence of cCMP) (Fig. 1C). As expected for the action of a gating activator, deactivation at \(-40 \text{ mV}\) was slower in the presence of cCMP (\( \tau_{\text{deact}} \) at \(-40 \text{ mV}\) = 462 \pm 23.5 ms (n = 13) versus 363 \pm 23 ms (n = 15) in the absence of cCMP) (Fig. 1, C and D).

Among the four members of the HCN channel family, only HCN2 and HCN4 are profoundly regulated by cAMP, whereas HCN1 and HCN3 are only weakly sensitive (if at all) to cAMP (1). We tested whether a similar range of sensitivity is also seen for cCMP. Indeed, there was no significant effect of cCMP on the \( V_{0.5} \) of HCN1 (Fig. 2, A and D) and HCN3 (Fig. 2, B and D). In contrast, cCMP shifted the \( V_{0.5} \) of HCN4 to a comparable extent (about +10 mV) as observed for HCN2 (Fig. 2, C and D), cCMP, which is chemically closely related to cAMP, activated HCN2 and HCN4 in a comparable way as cAMP (supplemental Fig. S1).

Purine cyclic nucleotides activate HCN channels by binding in a reversible way to the intracellular CNBD. We tested whether cCMP exerts its effects in a similar manner. To this end, we measured currents from a HEK293 cell line stably expressing HCN4 using a planar patch-clamp setup (Port-a-Patch) that allows rapid internal perfusion and washout of solutions. Both cAMP (Fig. 3A) and cCMP (Fig. 3B) led to a profound increase in the current at \(-100 \text{ mV}\) that was fully reversible after washout. However, although a 100-fold higher concentration was used for cCMP than for cAMP (100 \( \mu \text{M}\) versus 1 \( \mu \text{M}\)), the maximal increase in the current amplitude obtained with cCMP was significantly smaller than that obtained with cAMP (\(-1.3\)-fold for cCMP versus 1.7-fold for cAMP at \(-100 \text{ mV}\)). The drop in the current amplitude below the initial level after washout of the cyclic nucleotides was caused by HCN channel rundown. It occurred to the same extent when the cells were perfused with internal solution without cyclic nucleotides (Fig. 3, A and B). The weaker effect of cCMP was also reflected in the extent of the shift in \( V_{0.5} \), which was +10.2 \pm 1.11 mV for 100 \( \mu \text{M}\) cAMP (n = 7; \( V_{0.5(-\text{cAMP})} = -111 \pm 4.24 \text{ mV} \) and \( V_{0.5(+\text{cAMP})} = -101 \pm 3.32 \text{ mV} \)) and +5.6 \pm 0.67 mV for 100 \( \mu \text{M}\) cCMP (n = 8; \( V_{0.5(-\text{cCMP})} = -110 \pm 2.32 \text{ mV} \) and \( V_{0.5(+\text{cCMP})} = -105 \pm 2.56 \text{ mV} \)). The more negative \( V_{0.5} \) values obtained with the planar patch-clamp technique (Fig. 3, C and D) compared with the conventional whole-cell mode (Fig. 2, C and D) probably reflect the fact that phosphatidylinositol-4,5-bisphosphate, an important coactivator of HCN channel gating, is washed out during the internal perfusion in the planar patch-
**cCMP is an Activator of HCN Channels**

**Interaction of cCMP with the CNBDs of HCN Channels**—We used computer-based docking approaches to examine the binding of cCMP and cAMP to the crystal structures of the CNBDs of HCN2 (27) and HCN4 (28, 33, 34). Fig. 4 (A and B) shows molecular surface illustrations of the HCN2 CNBD with either cAMP or cCMP. There was no principal difference in the analogous models for HCN4 (data not shown). The residues of the CNBD that interacts with cyclic nucleotides are same for cCMP and cAMP. Specific interactions of Arg-591 and Thr-592 with the phosphor-bound oxygens of the sugar moiety and between the hydroxyl group and Gly-581/Glu-582 are observed (dashed blue lines). The aromatic part of the ligand interacts with Val-564 and Arg-632. The non-polar hydrogen atoms of Arg-632 potentially contribute to π stacking of cAMP more than cCMP (dashed red lines). Less specific interactions are observed for Ile-545, Leu-574, Phe-580, Ile-583, Cys-584, Ala-593, and Val-595 (data not shown). Three different placement methods (see “Experimental Procedures”) were used to estimate the difference in binding energies. A lower affinity was estimated for cCMP than for cAMP ($\Delta \Delta G = 0.53$ kcal/mol for HCN2 and 1.46 kcal/mol for HCN4), averaging over the three methods. In agreement with this difference, the apparent experimental affinity of cCMP was ~30 times lower than that of cAMP (for HCN2, $EC_{50}(\text{cCMP}) = 29 \mu M$ and $EC_{50}(\text{cAMP}) = 1 \mu M$) (Fig. 5, A and B). Moreover, in agreement with the planar patch-clamp measurements, the maximal shift in $V_{0.5}$ by cCMP at the saturating concentration was only ~60% of that by cAMP (Fig. 5B). Together, these results suggest that cCMP is a partial agonist of HCN channels. To confirm this hypothesis, we measured the effect of cCMP in the presence of cAMP (Fig. 5, C–F) on heterologously expressed HCN2 channels. As expected for a partial agonist, saturating concentrations of cCMP, when applied together with high concentrations of cAMP, led to a slight but highly significant hyperpolarizing shift in $V_{0.5}$ compared with the $V_{0.5}$ seen with high concentrations of cAMP alone (shifts in $V_{0.5}$ of 12.6 ± 0.6 mV with 10 $\mu M$ cAMP, 8.56 ± 0.5 mV with 10 $\mu M$ cAMP and 1 mM cCMP, and 7.7 ± 0.5 mV with 1 mM cCMP) (Fig. 5, A, C and D). The cyclic nucleotides exerted an additive effect on the activation of HCN channels when both were applied together at lower concentrations, around their respective $EC_{50}$ values. Under these conditions, $V_{0.5}$ was shifted to more depolarized potentials compared with the application of cAMP alone (shifts in $V_{0.5}$ of 5.8 ± 0.7 mV with 1 $\mu M$ cAMP, 7.0 ± 0.5 mV with 50 $\mu M$ cCMP, and 10.0 ± 0.8 mV with 1 $\mu M$ cAMP and 50 $\mu M$ cCMP) (Fig. 5, E and F). To exclude that cCMP effects result from interactions with residues outside of the CNBD, we determined the activation curve in an HCN2 mutant that is deficient for cAMP binding due to the presence of R591E and T592A (HCN2(R591E/T592A)) (Fig. 5, G and H) (34). In this mutant cCMP, no longer led to a shift in $V_{0.5}$, indicating that an intact CNBD is required for conferring the modulatory action of cCMP.

**cCMP Increases the Frequency of Sinoatrial Pacemaker Potentials**—We wondered whether cCMP modulation of HCN channels could exert physiological effects in vivo. To this end, we determined the effect of cCMP on sinoatrial pacemaking (Fig. 6). Fig. 6A shows representative pacemaker potentials of murine SAN cells under control conditions and after intracellular application of 1 mM cCMP or cAMP via the patch pipette. Both cyclic nucleotides significantly increased the firing rate of HCN channels. To confirm this hypothesis, we measured the firing frequency induced by co-application of saturating concentrations of cCMP and cAMP, leading to a slight but highly significant hyperpolarizing shift in $V_{0.5}$ compared with the application of cAMP alone (shifts in $V_{0.5}$ of 12.6 ± 0.6 mV with 10 $\mu M$ cAMP, 8.56 ± 0.5 mV with 10 $\mu M$ cAMP and 1 mM cCMP, and 7.7 ± 0.5 mV with 1 mM cCMP) (Fig. 5, A, C and D). The cyclic nucleotides exerted an additive effect on the activation of HCN channels when both were applied together at lower concentrations, around their respective $EC_{50}$ values. Under these conditions, $V_{0.5}$ was shifted to more depolarized potentials compared with the application of cAMP alone (shifts in $V_{0.5}$ of 5.8 ± 0.7 mV with 1 $\mu M$ cAMP, 7.0 ± 0.5 mV with 50 $\mu M$ cCMP, and 10.0 ± 0.8 mV with 1 $\mu M$ cAMP and 50 $\mu M$ cCMP) (Fig. 5, E and F). To exclude that cCMP effects result from interactions with residues outside of the CNBD, we determined the activation curve in an HCN2 mutant that is deficient for cAMP binding due to the presence of R591E and T592A (HCN2(R591E/T592A)) (Fig. 5, G and H) (34). In this mutant cCMP, no longer led to a shift in $V_{0.5}$, indicating that an intact CNBD is required for conferring the modulatory action of cCMP.

**DISCUSSION**

Here, we have demonstrated that the pyrimidine cyclic nucleotide cCMP is an activator of HCN channel gating. Within the HCN channel family, HCN2 and HCN4, the two channels that are also known to be regulated by cAMP and...
cGMP, displayed profound regulation by cCMP. In contrast, gating of HCN1 and HCN3 was not affected by cCMP. cCMP induced a shift in the HCN2 and HCN4 activation curves by about $\pm 100 \text{ mV}$. This voltage shift is significantly smaller than that observed for cAMP ($\pm 12 \text{ mV}$), suggesting that cCMP is a partial agonist of HCN channels. In agreement with this model, in HCN2, cCMP diminished the maximal voltage shift induced by cAMP when co-applied with cAMP. Beside its effects on the voltage dependence of activation, cCMP affected gating kinetics. Like cAMP, cCMP accelerated the speed of activation, whereas it slowed down channel deactivation. On a structural level, the stimulatory effect of cCMP requires the presence of a functional CNBD because it was completely lost if two key residues that are required for cyclic nucleotide binding were mutated (R591E/T592A in HCN2). Our docking experiments suggest that cCMP interacts with the same principal residues within the CNBDs of HCN2 and HCN4 as cAMP. The apparent affinities determined in our electrophysiological experiments are $1 \text{ mM}$ for cAMP and $30 \text{ mM}$ for cCMP, thus yielding an approximate difference of $\Delta \Delta G = 2.0 \text{ kcal/mol}$. The computational estimate of 0.5–1.5 kcal/mol determined in docking experiments matches this value quite well. It should be noted that docking approaches in general can hardly take the flexibility of the binding pocket into account, including rearrangements after ligand binding, as they are well documented for other cyclic nucleotide-binding proteins (36–38). Furthermore, it is difficult to estimate absolute binding energies, as scoring functions are always calibrated to a specific training set. Nevertheless, the good agreement found in our study gives great confidence that the binding mode of the ligands and their relative difference in affinity are produced correctly. In our docking model, the anchoring of the sugar moieties within the binding pocket of HCN2 or HCN4 is almost identical for cAMP and cCMP. The observed difference in binding affinity most likely is based on how the delocalized $\pi$ systems (38) of cAMP and cCMP interact with hydrophobic parts of Val-564 and Arg-632. Consequently, the ligand is shifted slightly within the binding pocket, allowing a slightly better fit for cAMP than for cCMP. Molecular dynamics simulation in combination with mutagenesis demonstrated that Arg-632 is essential for high ligand efficacy due to its selective stabilization of cyclic nucleotide binding to the open channel (39). Thus, it is tempting to speculate that the somewhat weaker interaction of Arg-632 with cCMP compared with cAMP may explain why cCMP is only a partial agonist of HCN channels.

The physiological relevance of cCMP is currently discussed controversial. So far, specific enzymes that synthesize or degrade cCMP have not been identified. However, there is recent evidence that soluble guanylyl cyclases possess the capacity to synthesize cCMP in the presence of the activator nitric oxide (40). Moreover, it was shown that cCMP can relax vascular smooth muscle and inhibit platelet activation via activation of cyclic nucleotide-dependent protein kinases (19–20). The exact concentrations of cCMP and cUMP in intact tissues have not been determined. However, in cell lines from various species and tissue origins, cCMP concentrations under basal conditions are in the same range as cGMP concentrations, ranging from 30 to 70 $\text{ mM}$ (18). These concentrations are well in the range required to modulate HCN channel activity ($EC_{50(cCMP)} = 30 \text{ mM}$). In support of a physiological role of cCMP, we have shown that this cyclic pyrimidine has the potential to increase heart rate by activating sinoatrial $I_f$ and thereby enhance the SDD in SAN pacemaker cells. In this context, it is important to note that owing to its partial agonistic activity, cCMP action could be complex in a physiological setting. If present alone, cCMP is an activator of HCN channel
gating. If cCMP and cAMP are both present in the microenvironment of an HCN channel complex, cCMP could either enhance or dampen cAMP effects depending on the actual concentrations of both cyclic nucleotides. It should also be considered that cCMP could exert some of its physiological effects by activating PKA (19). For example, phosphorylation of calcium channels (Cav1.3), ryanodine receptors, or phospholamban by PKA would also accelerate diastolic depolarization (for review, see Ref. 41). In neuronal circuits involving HCN channel activity, cCMP up-regulation of $I_h$ may also be relevant. Further studies will be required to dissect the specific contribution of cAMP- and cCMP-dependent regulation of HCN channel activity. To this end, it will be necessary to determine the formation and degradation of cyclic nucleotides at high temporal and spatial resolution. This work provides an important basis for such follow-up studies because it indicates that cCMP effects must be taken into account to obtain a comprehensive view of physiological processes involving HCN channels.

Acknowledgment—We thank B. Noack for excellent technical assistance.
REFERENCES

1. Biel, M., Wahl-Schott, C., Michalakis, S., and Zong, X. (2009) Hyperpolarization-activated cation channels: from genes to function. Physiol. Rev. 89, 847–885.

2. DiFrancesco, D. (2010) The role of the funny current in pacemaker activity. Circ. Res. 106, 834–846.

3. Frère, S. G., Kuisle, M., and Lütthi, A. (2004) Regulation of recombinant and native hyperpolarization-activated cation channels. Mol. Neurobiol. 30, 279–305.

4. Brown, H., and DiFrancesco, D. (1980) Voltage-clamp investigations of membrane currents underlying pacemaker activity in rabbit sinoatrial node. J. Physiol. 308, 331–351.

5. Ludwig, A., Zong, X., Jeglitsch, M., Hofmann, F., and Biel, M. (1998) A family of hyperpolarization-activated mammalian cation channels. Nature 393, 587–591.

6. Santana, B., Liu, D. T., Yao, H., Bartsch, D., Kandel, E. R., Siegelbaum, S. A., and Tibbs, G. R. (1998) Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. Cell 93, 717–729.

7. Gauss, R., Seifert, R., and Kaupp, U. B. (1998) Molecular identification of a hyperpolarization-activated channel in sea urchin sperm. Nature 393, 583–587.

8. Brown, H. F., DiFrancesco, D., and Noble, S. J. (1979) How does adrenaline accelerate the heart? Nature 280, 235–236.

9. DiFrancesco, D., Ducouret, P., and Robinson, R. B. (1989) Muscarninic modulation of cardiac rate at low acetylcholine concentrations. Science 243, 669–671.

10. McCormick, D. A., and Bal, T. (1997) Sleep and arousal: thalamocortical working memory networks by inhibiting cAMP-HCN channel signaling. J. Physiol. 501, 285–305.

11. Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Chen, Z., and Biel, M. (2005) A novel mechanism of modulation of hyperpolarization-activated cyclic nucleotide-gated channels by Src kinase. J. Biol. Chem. 280, 34224–34232.

12. Herrmann, S., Stieber, J., Stöckl, G., Hofmann, F., and Ludwig, A. (2007) HCN4 provides a “depolarization reserve” and is not required for heart rate acceleration in mice. EMBO J. 26, 4423–4432.

13. Herrmann, S., Stieber, J., Stöckl, G., Hofmann, F., and Ludwig, A. (2007) HCN4 provides a “depolarization reserve” and is not required for heart rate acceleration in mice. EMBO J. 26, 4423–4432.

14. Barry, P. H. (1994) ICalc, a software package for calculating liquid junction potential corrections in patch-clamp, intracellular, epithelial, and bilayer measurements and for correcting junction potential measurements. J. Neurosci. Methods 51, 107–116.

15. Bucchi, A., Barusscotti, M., Robinson, R. B., and DiFrancesco, D. (2007) Modulation of rate by autonomic agonists in SAN cells involves changes in diastolic depolarization and the pacemaker current. J. Mol. Cell. Cardiol. 43, 39–48.

16. Brüggemann, A., Stoelzel, S., Baulies, J., and Fertig, N. (2006) Microchip technology for automated and parallel patch-clamp recording. Small 2, 840–846.

17. Zagotta, W. N., Oliveri, N. B., Black, K. D., Young, E. C., Olson, R., and Gouaux, E. (2003) Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature 425, 200–205.

18. Loliato, M., Nardini, M., Gazzarrini, S., Möller, S., Bertinet, D., Herberg, F. W., Bolognesi, M., Martin, H., Fassolini, M., Bertrand, A. J., Arrigoni, C., Thiel, G., and Moroni, A. (2011) Tetramerization dynamics of C-terminal domain underlies isoform-specific CAMP gating in hyperpolarization-activated cyclic nucleotide-gated channels. J. Biol. Chem. 286, 44811–44820.

19. Liang, J., Edelsbrunner, H., Fu, P., Sudhakar, P. V., and Subramaniam, S. (1998) Analytical shape computation of macromolecules. II. Inaccessible cavities in proteins. Proteins 33, 18–29.

20. Pian, P., Bucchi, A., Decostanzo, A., Robinson, R. B., and Siegelbaum, S. A. (2007) Modulation of cyclic nucleotide-regulated HCN channels by PIP2 and receptors coupled to phospholipase C. Pflugers Arch. 455, 125–145.

21. Zolles, G., Häußler, N., Wenzel, D., Weisser-Thomas, J., Fleischmann, B. K., Roep, J., and Fakler, B. (2006) Pacemaking by HCN channels requires interaction with phosphoinositides. Neuron 52, 1072–1036.

22. Pian, P., Bucchi, A., Robinson, R. B., and Siegelbaum, S. A. (2006) Regulation of gating and rundown of HCN hyperpolarization-activated channels by exogenous and endogenous PIP2. J. Gen. Physiol. 128, 593–604.

23. Xu, X., Vysotskaya, Z. V., Liu, Q., and Zhou, L. (2010) Structural basis for the cAMP-dependent gating in the human HCN4 channel. J. Biol. Chem. 285, 37082–37091.

24. Chen, S., Wang, J., and Siegelbaum, S. A. (2001) Properties of hyperpolarization-activated pacemaker current defined by coassembly of HCN1 and HCN2 subunits and basal modulation by cyclic nucleotide. J. Gen. Physiol. 117, 491–504.

25. Ludwig, A., Zong, X., Stieber, J., Hullin, R., Hofmann, F., and Biel, M. (1999) Two pacemaker channels from human heart with profoundly different activation kinetics. EMBO J. 18, 2323–2329.

26. Schünke, S., Stoldt, M., Lecher, J., Kaup, U. B., and Willbold, D. (2011) Structural insights into conformational changes of a cyclic nucleotide-binding domain in solution from Mesorhizobium loti K1 channel. Proc. Natl. Acad. Sci. U.S.A. 108, 6121–6126.

27. Schünke, S., Stoldt, M., Novak, K., Kaup, U. B., and Willbold, D. (2009) Solution structure of the Mesorhizobium loti K1 channel cyclic nucleotide-binding domain in complex with cAMP. EMBO Rep. 10, 779–735.

28. Rozas, I., Alkorta, I., and Elguero, J. (1997) Unusual hydrogen bonds: H2O2-OH2O2-OH2O2-OH2O2 interactions. J. Phys. Chem. A 101, 9457–9463.

29. Zhou, L., and Siegelbaum, S. A. (2007) Gating of HCN channels by cyclic nucleotides: residue contacts that underlie ligand binding, selectivity, and efficacy. Structure 15, 665–671.

30. Bart, K. Y., Burhenn, H., Kaup, V., Stotler, J., and Seifert, R. (2011) Structural insights into conformational changes of a cyclic nucleotide-binding domain in solution from Mesorhizobium loti K1 channel. Proc. Natl. Acad. Sci. U.S.A. 108, 6121–6126.

31. K1 channel cyclic nucleo-

32. Wambacher, H., Beste, K. Y., Bucchi, A., Robinson, R. B., and Siegelbaum, S. A. (2009) Gating of HCN channels by cyclic nucleotides: residue contacts that underlie ligand binding, selectivity, and efficacy. Structure 15, 665–671.